Lv1
40 积分 2023-09-22 加入
Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025
3个月前
已完结
Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer
3个月前
已完结
Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer
3个月前
已完结
N-[3-(4-(2-methoxyphenyl) piperazine-1-yl) propyl]-heteroaromatic carboxamide as selective α1A/1D-adrenoceptor antagonists: SAR study and metabolic stability evaluation
3个月前
已完结
Inhibition of AKR1Cs by liquiritigenin and the structural basis
3个月前
已完结
AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer
5个月前
已完结
Discovery and Optimization of a Covalent AKR1C3 Inhibitor
5个月前
已完结
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
5个月前
已完结
Prostate cancer
5个月前
已完结
Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer
5个月前
已完结
皖公网安备34019202002308
